Oral Weekly GS-1720 + GS-4182 vs Biktarvy in Virologically Suppressed HIV-1

Phase 3, randomised trial in Human immunodeficiency virus infection type 1 comparing Weekly GS-1720 + GS-4182 with Daily Biktarvy (2 arms). Primary endpoints: Phase 2: Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 (FDA snapshot) and Phase 3: Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 (FDA snapshot). Planned start Feb 2025; status: authorised.